Home
Arnold & Porter
Daniel A. Kracov
Daniel A. Kracov
Arnold & Porter
Senate Judiciary Committee Targeting Alleged "Anticompetitive" Biopharmaceutical Industry Practices
15 Mar 2023 | United States
NAD Reminds Industry That The Door Is Open For Competitor Prescription Drug Advertising Challenges
06 Feb 2023 | United States
US FDA User Fee Riders Make It Across The Line: A Guide To The Food And Drug Omnibus Reform Act (FDORA)
03 Jan 2023 | United States
FDA Releases Significantly Revised Final Clinical Decision Support Software Guidance And Related Changes
24 Oct 2022 | United States
Medical Devices & Consumer Health Products 2022
28 Sep 2022 | United States
Pharmaceutical Advertising 2022
14 Jul 2022 | United States
FDA Proposes Rule On Use Of Innovative Technologies And Other Conditions Of Use To Expand Options For Nonprescription Drug Products
08 Jul 2022 | United States
Life Sciences 2022
07 Apr 2022 | United States
The PREP Act And COVID-19: Two Years Later
28 Mar 2022 | United States
Recent US Court Decision Threatens Orphan Exclusivity And Marketing Approval For Certain Orphan Drugs
01 Mar 2022 | United States
FDA Releases Proposed Rules On National Licensure Standards For Wholesale Drug Distributors And Third-Party Logistics Providers (3PLs)
16 Feb 2022 | United States
Research Roundup: FDA Uses Fall And Winter 2021 To Release Significant New Guidance Governing Hot-Button Life Sciences Research Topics
27 Dec 2021 | United States
In House Warrior With Daniel Kracov (Podcast)
24 Nov 2021 | United States
Medical Devices & Consumer Health Products 2021: Trends & Developments
03 Oct 2021 | United States
FDA Seeks To Deepen Engagement With USPTO On Pharmaceutical Patents
28 Sep 2021 | United States
FDA Seeks Comments On Transition Of Certain Drugs To Device Status Following Genus DC Circuit Decision
13 Aug 2021 | United States
Update: Use Of Real-World Evidence In FDA Approvals And Product Promotion
29 Jul 2021 | United States
Real-World Evidence And Its Use In Advertising Of Medicinal Products In The EU And US
15 Jul 2021 | Worldwide
Pharmaceutical Advertising 2021: USA Chapter
15 Jul 2021 | United States
The VALID Act & 21st Century Cures 2.0: What Industry Needs To Know
07 Jul 2021 | United States
< 1 2 3 4 >
20%
Very Popular: This author falls within the Top 20% for the below topics and industry categories
Based on Mondaq users readership, this author is ranked as VERY POPULAR in United States for the topics, user groups and industry sectors listed below*:
Topics
  • Food and Drugs Law
  • Healthcare
  • Product Liability & Safety
  • Food, Drugs, Healthcare, Life Sciences
  • Consumer Protection
  • Life Sciences, Biotechnology & Nanotechnology
* Rankings are based on analysis of the last 12 months of Mondaq readership data across more than 25,000 contributing authors. To be ranked ‘Very Popular’ an author must be in the top 20% of results within the selected criteria.
Contact Details
Washington, DC
Email Website
601 Mass. Ave., NW
Washington, DC
United States
Telephone: 1-202-9425000

  © Mondaq® Ltd 1994 - 2023. All Rights Reserved.